SCHEMBL709306

SCHEMBL709306

O=C1CSc2cccnc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
PDE3B Q13370 2/20 0.43
PDE3A Q14432 2/20 0.43
MAOA P21397 6/20 0.41
MAOB P27338 6/20 0.41
EPHX2 P34913 1/20 0.41
KIF11 P52732 1/20 0.39
ADAMTS5 Q9UNA0 2/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTT P42858 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18173717 0.75 SMN1; SMN2 (0.48) GAAPOLBCYP1A2SMN1; SMN2ALDH1A1
SCHEMBL17007592 0.72 GAA (0.41) CYP11B1CYP11B2PDE3BPDE3AMAOA
SCHEMBL12210281 0.72 TDP1 (0.42) CYP11B1CYP11B2GAA
SCHEMBL6080268 0.71 ALDH1A1 (0.46) CYP11B1CYP11B2PDE3BPDE3AMAOA
SCHEMBL30032262 0.71 PDE3B (0.40) CYP11B1CYP11B2PDE3BPDE3AMAOA
SCHEMBL31243452 0.71
SCHEMBL3579949 0.71
SCHEMBL4142652 0.70 PDE3B (0.52) CYP11B1CYP11B2PDE3BPDE3AMAOA
SCHEMBL632922 0.70 MAOB (0.40) CYP11B1CYP11B2PDE3BPDE3AMAOA
SCHEMBL4142650 0.70 PDE3B (0.46) CYP11B1CYP11B2PDE3BPDE3AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592334-B2 Antibacterial agents GLAXO GROUP LIMITED (GB) 2009-09-22 US claimed
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 US claimed
EP-1799676-A2 NEW BICYCLIC ANTIBIOTICS Actelion Pharmaceuticals Ltd. (CH) 2007-06-27 EP claimed
WO-2006032466-A2 NEW BICYCLIC ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2006-03-30 WO claimed
US-20230312474-A1 PHENOL DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-10-05 US disclosed
US-20230312474-A1 PHENOL DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-10-05 US disclosed
EP-4206184-A1 PHENOL DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-07-05 EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
EP-4023293-A1 2-AMINOQUINAZOLINONE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2022-07-06 EP disclosed
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-11331369-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2022-05-17 US disclosed
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
WO-2008006648-A1 SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2008-01-17 WO disclosed
US-7312212-B2 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2007-12-25 US disclosed
US-20070287701-A1 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli SMITHKLINE BEECHAM CORPORATION 2007-12-13 US disclosed
WO-2007118130-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2007-10-18 WO disclosed
WO-2007115947-A1 PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2007-10-18 WO disclosed
US-20070185153-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
US-20070135422-A1 Nitrogen-containing bicycle heterocycles for use as antibacterials SMITHKLINE BEECHAM P.L.C. 2007-06-14 US disclosed
US-20060041123-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287701-A1 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli NPM1, TOP1, HMGB1 CYP11B1 3034/4885CYP11B2 2921/4885PDE3B 3368/4885
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 CYP11B1 4271/4885CYP11B2 4107/4885PDE3B 361/4885
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 CYP11B1 1212/4885CYP11B2 950/4885PDE3B 1325/4885
US-20070135422-A1 Nitrogen-containing bicycle heterocycles for use as antibacterials NRDC, NUCB2, NISCH CYP11B1 1045/4885CYP11B2 817/4885PDE3B 1922/4885
US-20070185153-A1 COMPOUNDS NRDC, NISCH, MRPL21 CYP11B1 2259/4885CYP11B2 1928/4885PDE3B 4347/4885
US-20230312474-A1 PHENOL DERIVATIVE TYR, NCOR1, BET1 CYP11B1 155/4885CYP11B2 92/4885PDE3B 3386/4885
US-20060041123-A1 Antibacterial agents NQO2, NRDC, IFNG CYP11B1 3693/4885CYP11B2 3506/4885PDE3B 2564/4885
US-11331369-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 CYP11B1 1789/4885CYP11B2 1946/4885PDE3B 1026/4885
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION LTB4R, C5, C3AR1 CYP11B1 1681/4885CYP11B2 2054/4885PDE3B 998/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 CYP11B1 732/4885CYP11B2 417/4885PDE3B 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.